A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients - PubMed (original) (raw)
Clinical Trial
. 2001 Sep;16(9):1879-84.
doi: 10.1093/ndt/16.9.1879.
Affiliations
- PMID: 11522873
- DOI: 10.1093/ndt/16.9.1879
Clinical Trial
A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients
D W Johnson et al. Nephrol Dial Transplant. 2001 Sep.
Abstract
Background: Concomitant iron supplementation is required in the great majority of erythropoietin (Epo)-treated patients with end-stage renal failure. Intravenous (i.v.) iron supplementation has been demonstrated to be superior to oral iron therapy in Epo-treated haemodialysis patients, but comparative data in iron-replete peritoneal dialysis (PD) patients are lacking.
Methods: A 12-month, prospective, crossover trial comparing oral and i.v. iron supplementation was conducted in all Princess Alexandra Hospital PD patients who were on a stable dose of Epo, had no identifiable cause of impaired haemopoiesis other than uraemia, and had normal iron stores (transferrin saturation >20% and serum ferritin 100-500 mg/l). Patients received daily oral iron supplements (210 mg elemental iron per day) for 4 months followed by intermittent, outpatient i.v. iron infusions (200 mg every 2 months) for 4 months, followed by a further 4 months of oral iron. Haemoglobin levels and body iron stores were measured monthly.
Results: Twenty-eight individuals were entered into the study and 16 patients completed 12 months of follow-up. Using repeated-measures analysis of variance, haemoglobin concentrations increased significantly during the i.v. phase (108+/-3 to 114+/-3 g/l) compared with each of the oral phases (109+/-3 to 108+/-3 g/l and 114+/-3 to 107+/-4 g/l, P<0.05). Similar patterns were seen for both percentage transferrin saturation (23.8+/-2.3 to 30.8+/-3.0%, 24.8+/-2.1 to 23.8+/-2.3%, and 30.8+/-3.0 to 26.8+/-2.1%, respectively, P<0.05) and ferritin (385+/-47 to 544+/-103 mg/l, 317+/-46 to 385+/-47 mg/l, 544+/-103 to 463+/-50 mg/l, respectively, P=0.10). No significant changes in Epo dosages were observed throughout the study. I.v. iron supplementation was associated with a much lower incidence of gastrointestinal disturbances (11 vs 46%, P<0.05), but exceeded the cost of oral iron treatment by 6.5-fold.
Conclusions: Two-monthly i.v. iron infusions represent a practical alternative to oral iron and can be safely administered to PD patients in an outpatient setting. Compared with daily oral therapy, 2-monthly i.v. iron supplementation in PD patients was better tolerated and resulted in superior haemoglobin levels and body iron stores.
Similar articles
- Oral versus intravenous iron supplementation in peritoneal dialysis patients.
Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM. Johnson DW, et al. Perit Dial Int. 2001;21 Suppl 3:S231-5. Perit Dial Int. 2001. PMID: 11887827 - A randomized controlled study of iron supplementation in patients treated with erythropoietin.
Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. Macdougall IC, et al. Kidney Int. 1996 Nov;50(5):1694-9. doi: 10.1038/ki.1996.487. Kidney Int. 1996. PMID: 8914038 Clinical Trial. - Iron status and iron supplementation in peritoneal dialysis patients.
Vychytil A, Haag-Weber M. Vychytil A, et al. Kidney Int Suppl. 1999 Mar;69:S71-8. doi: 10.1046/j.1523-1755.1999.055suppl.69071.x. Kidney Int Suppl. 1999. PMID: 10084290 Review. - Intravenous versus oral iron supplementation in peritoneal dialysis patients.
Johnson DW. Johnson DW. Perit Dial Int. 2007 Jun;27 Suppl 2:S255-60. Perit Dial Int. 2007. PMID: 17556315 Review.
Cited by
- Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review. - Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study.
Portolés-Pérez J, Durá-Gúrpide B, Merino-Rivas JL, Martín-Rodriguez L, Hevia-Ojanguren C, Burguera-Vion V, Yuste-Lozano C, Sánchez-García L, Rodriguez-Palomares JR, Paraiso V; GCDP Study Group. Portolés-Pérez J, et al. Clin Kidney J. 2019 Nov 22;14(1):174-180. doi: 10.1093/ckj/sfz153. eCollection 2021 Jan. Clin Kidney J. 2019. PMID: 33564416 Free PMC article. - Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.
Mitsopoulos E, Lysitska A, Pateinakis P, Lamprou V, Intzevidou E, Minasidis I, Katsaounou C, Kougioumtzidou O, Anagnostou N, Lemonidis N, Papadopoulou D. Mitsopoulos E, et al. Int Urol Nephrol. 2020 Feb;52(2):387-392. doi: 10.1007/s11255-019-02362-4. Epub 2020 Jan 1. Int Urol Nephrol. 2020. PMID: 31894555 - A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. Birgegård G, et al. Pharmacotherapy. 2016 Apr;36(4):402-14. doi: 10.1002/phar.1729. Epub 2016 Apr 1. Pharmacotherapy. 2016. PMID: 26927900 Free PMC article. Clinical Trial. - Chapter 2: Use of iron to treat anemia in CKD.
[No authors listed] [No authors listed] Kidney Int Suppl (2011). 2012 Aug;2(4):292-298. doi: 10.1038/kisup.2012.34. Kidney Int Suppl (2011). 2012. PMID: 25018949 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials